To kick off the new year, we are releasing new Cord Blood Banking Awareness Facts, from our partnership with Save the Cord Foundation. As a refresher, this campaign aims to educate currently expecting parents, as well as future parents, grandparents, siblings, and friends, about the medical benefits of cord blood preservation. Below is a new collection of facts that aid our efforts in spreading awareness.
Top 10 Most Shared Mesenchymal Stem Cell (MSC) Articles
The field of mesenchymal stem cell research (MSC) has been rapidly expanding in recent years, bringing to market new concepts for treatments and applications. Indeed, MSCs are now one of the most commonly pursued stem types for clinical purposes.
Therefore, this post considers the top ten most frequently shared MSC articles over a 12 month period. The purpose of this analysis is to determine the type of MSC content that is most widely shared across social media platforms, as well as the authors and publishers of these articles.
Methodology for Determining the Top 10 MSC Articles
The top ten most shared mesenchymal stem cell articles are listed below. The share data is generated using Facebook, LinkedIn, Twitter, Google+, and Pinterest shares, and has been aggregated using the service BuzzSumo.com, a social analytics tool that is designed to assist content marketers and SEO specialists with discovering engaging content opportunities. [Read more…]
Wishing All of BioInformant’s Stem Cell Clients and Partners a Prosperous 2016!
As we are now just hours from 2016, I wanted to take a moment to wish all of BioInformant’s stem cell clients and partners a prosperous New Year! 2015 was an incredible year for us, in that we introduced hundreds of new clients to our products and services, sponsored and attended a wide range of stem cell industry conferences, expanded our portfolio of products, and reached new levels of visibility in the marketplace.
However, the single important metric to us is that we fueled massive new levels of success for our clients. On average, our clients that claimed stem cell or cord blood market intelligence increased revenue 3X faster than had done in prior years. There are many reasons why market intelligence works to increase revenue. It eliminates unnecessary expenses by identifying market segments that are shrinking (or experiencing slow growth), and at that same time, it drives new revenue by identifying promising new markets to target.
However, in my experience, the single biggest power of market intelligence is that it positions you to make smarter decisions, faster. [Read more…]
Cord Tissue Storage Impacted by the Global Mesenchymal Stem Cell (MSC) Market
For our clients in the cord blood banking sector, we highly recommend that you review the report, “Mesenchymal Stem Cells – Advances & Applications.” This MSC report will uniquely inform you about opportunities related to cord tissue storage and future applications with cord tissue derived MSCs.
Remember, to benefit from the global MSC market, you need to anticipate and serve the needs of your clients – or other cord blood banks will.
Key questions answered in the report are:
(Regenerative Medicine = RM; Cell Therapy= CT)
Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
With a market capitalization of more than $350 million, Ocata Therapeutics is a major player in the stem cell space. Based in Marlborough, Massachusetts, it is a clinical stage biotech company that develops a range of regenerative therapies for the treatment of ophthalmologic conditions. By 2010, Ocata Therapeutics (at the time called “Advanced Cell Therapy”) began experimenting with induced pluripotent stem cells (iPSCs). This was only four years after research and experimentation using mouse cells at Kyoto University first generated iPSCs in 2006, and only three years after a series of follow-up experiments done at Kyoto University successfully transformed human adult cells into iPSCs in 2007.
Due to concerns with the use of iPSCs for therapeutic applications, the company shifted its approach to using human embryonic stem cells (hESCs) for clinical trial purposes, as well as other pluripotent cell types.
In major news released on December 28, 2015, Ocata Therapeutics stated in a company press release that “early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University…presenting a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC).” [Read more…]
- « Previous Page
- 1
- …
- 277
- 278
- 279
- 280
- 281
- …
- 307
- Next Page »